Novartis

View All

Beta-Thalassemia-Market
Overcoming the prevailing unmet needs in Beta-Thalassemia Market

The current Beta-thalassemia market is experiencing the emergence of gene therapies as a one-time cure for the patients. Beta thalassemia is relatively a common heterogeneous autosomal recessive hereditary blood disorder. It is a common form of hemoglobinopathy characterized by ineffective erythropoiesis leadi...

Find More

Non-Small Cell Lung Cancer Market Insights
Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses

Non-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 million people in 2018 as per WHO, with lung cancer being the most commonly diagnosed one and accounting for the highest number of deaths (1.76...

Find More

COVID-19-pipeline-development
COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market

The U.S. FDA has given its nod to Seattle Genetics for its Tukysa (tucatinib) for advanced unresectable or metastatic HER2-positive breast cancer Genetics Tukysa (tucatinib) is a tyrosine kinase inhibitor of the HER2 protein, administered orally in combination with chemotherapy agents trastuzumab and capec...

Find More

CAR-T Cell Therapy Market In ALL- Acute lymphocytic leukemia
Future Perspectives Of CAR-T Cell Therapy Market In Acute Lymphoblastic Leukemia (ALL)

DelveInsight estimates by 2030, the Car-T cell therapy market in Acute lymphoblastic leukaemia would approximate to USD 1,315.7 million in the 6MM (U.S. and EU5 including UK, Germany, Italy, France and Spain), emerging as a multi-billion-dollar industry. Acute lymphocytic leukemia (ALL) is a tumor that afflic...

Find More

Soft Tissue Sarcoma
Soft Tissue Sarcoma: A rare malignancy

What does a yellow ribbon signify? It symbolizes support for Sarcoma patients. Sarcoma – an umbrella term for several forms of cancer that occur in muscles or bones – is a rare form of cancer. There exist more than 70 types of sarcomas – mostly considered rare – classified on the basis of the type of tissue they af...

Find More

Healthcare scenario in MENA region
Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players

The Middle-East and North-Africa region (MENA), which encompasses some of the world’s wealthiest economies, extends unparalleled opportunities to multinational corporations with expertise in medical devices. There is a conspicuous disparity in the economic prowess across the countries, but most of them have shown r...

Find More

pharma news
Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey

A Philadelphia-based pharmaceutical, Annovis Bio, has raised USD12 million by listing its 2 million shares at USD 6 each. The company has managed to net USD 2 million more by offering 40% more shares.  The company plans to use the funds raised to address the unmet needs in the Alzheimer’s disease market...

Find More

Pharma news
Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102

The US FDA has recently granted Orphan Drug Designation to AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC. Imfinzi, a monoclonal antibody, binds and inhibits the interaction of PD-L1 with PD-1 and CD80. The drug blocks tumour’s immune-evading mechanism and releases the inhibiti...

Find More

Egg Allergy Market
Egg Allergy Market: Second most common food allergy but no approved therapy

Hen’s egg allergy is the second most common type of allergy after cow’s milk. In infants and young children, Egg poses as one of the most vital allergens degrading the quality of life.  As per estimates, as many as 2 per cents of children are allergic to eggs. However, around 70% of these children are fortunate ...

Find More

Pharma News
Toujeo to treat Type 1 Diabetes; TauRx for Alzheimer’s patients

Sanofi’s Toujeo has received FDA recommendation for its expanded use in Type 1 Diabetes. Toujeo is an insulin glargine injection to control the highs and lows of blood sugar in the body. Indicated to be used in adults and paediatric patients of age six and older. Earlier, the injection was considered suitab...

Find More